An $11 billion burst of biotech bids in just four days has fuelled expectations of a 2018 surge in life science deals as large drug-makers shop for promising assets from smaller rivals.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
